Press Releases Clene Inc.

Equities

CLNN

US1856341029

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-02 pm EDT			5-day change	1st Jan Change
0.4367 ^USD	-0.07%		+26.03%	+47.24%

Apr. 16	Clene Inc. and Clene Nanomedicine, Inc. Presented the Phase 2 VISIONARY-MS Long term Extension Study Results at the 2024 American Academy of Neurology Annual Meeting in Denver	CI
Mar. 15	Clene Inc. Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

IBN Announces From Lab to Launch Podcast Featuring Clene Inc. CEO Rob Etherington	May. 01	AQ
Clene : 2023 Annual Report to Stockholders	Apr. 17	PU
Evidence for Clene’s CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting	Apr. 16	AQ
IBN Announces First in Human Podcast Featuring Clene Inc. CEO Rob Etherington	Mar. 19	AQ
Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®	Mar. 15	AQ
Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights	Mar. 13	AQ
Clene to Present at the 36th Annual ROTH Conference	Mar. 07	AQ
Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024	Feb. 29	AQ
Clene Reports Significant Survival Benefit With CNM-Au8® Treatment in ALS EAP Compassionate Use Programs	Feb. 22	AQ
Clene Inc. announces positive results from CNM-Au8 results from MS trial	Feb. 05	AQ
Clene Reports Significant Improvement in Vision and Cognition With CNM-Au8® Treatment in VISIONARY-MS Trial Long-Term Open Label Extension	Jan. 08	AQ
Clene Provides Update on ALS Clinical Development Meeting With FDA	Dec. 21	AQ
Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8® Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension	Dec. 21	AQ
Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement In Neurodegenerative Diseases	Dec. 14	AQ
Clene Reports Third Quarter 2023 Financial Results and Operating Highlights	Nov. 07	AQ
National Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8® Study in ALS	23-10-05	AQ
Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Catalytic Neuroprotective Mechanism of Action	23-09-28	AQ
Clene to Present at Cantor Fitzgerald Annual Global Healthcare Conference	23-09-25	AQ
Clene Reports Significant Long-Term Survival Improvement From CNM-Au8 Treatment in HEALEY ALS Platform Trial Compared to PRO-ACT Historical Controls	23-09-25	AQ
Clene to Present at Upcoming September Conferences	23-08-30	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Clene Inc.

Equities

CLNN

US1856341029

Press Releases

Filters